Co-Diagnostics

Co-Diagnostics Cash Conversion

The Cash Conversion Rate (OCF/Net Income) of Co-Diagnostics (CODX) as of Nov 20, 2026 is 62.13 %. In the previous year, Cash Conversion Rate (OCF/Net Income) was 77.46 % — a change of -19.79% (lower).

Cash Conversion

62.13 %

YoY

-19.79%

Last updated:

Cash Conversion Rate (OCF/Net Income) of Co-Diagnostics is 2025 62.13 % . Cash Conversion Rate (OCF/Net Income) of Co-Diagnostics was 2024 77.46 % . It decreases by -19.79% lower compared to the previous year.

The Co-Diagnostics Cash Conversion history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Cash Conversion
Date
Cash Conversion
Jan 1, 2018
65.05 USD
Jan 1, 2019
89.18 USD
Jan 1, 2020
66.30 USD
Jan 1, 2021
112.07 USD
Jan 1, 2022
-46.13 USD
Jan 1, 2023
62.50 USD
Jan 1, 2024
77.46 USD
Jan 1, 2025
62.13 USD
The Co-Diagnostics Cash Conversion history
YEARCash ConversionYoY
62.13 %-19.79%
77.46 %+23.94%
62.50 %-235.47%
-46.13 %-141.17%
112.07 %+69.02%
66.30 %-25.65%
89.18 %+37.08%
65.05 %+40.98%
46.15 %-32.18%
68.04 %-9.16%
74.90 %-15.15%
88.27 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Co-Diagnostics Stock analysis

What does Co-Diagnostics do? Co-Diagnostics, Inc. develops and sells diagnostic tests using proprietary reagents and a test design system for diseases and pathogens including tuberculosis, drug-resistant tuberculosis, hepatitis B and C, malaria, dengue, HIV, and Zika virus. The company also markets self-contained lab systems (MDx devices) from other manufacturers. Its products are sold to laboratories and healthcare providers for molecular testing of organisms and genetic diseases, automating complex procedures in test development and administration. The firm generates revenue through the sale of diagnostic reagents, validated tests, and MDx devices. The company's diagnostic technology focuses on nucleic acid detection and analysis, enabling molecular testing for various pathogens and genetic conditions. Its proprietary system allows for the design and validation of tests in-house, which are then marketed to healthcare institutions. Revenue streams include reagent sales, test kits, and equipment from partner manufacturers. Co-Diagnostics, Inc. targets laboratories and healthcare providers as key customers for its diagnostic solutions. The firm's products are designed to streamline molecular testing processes, reducing the complexity of traditional methods. This approach supports the company's revenue model based on direct sales of its proprietary tests and complementary equipment. Co-Diagnostics is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Co-Diagnostics stock

Cash Conversion Rate (OCF/Net Income) of Co-Diagnostics is 62.13 % in 2025.

Cash Conversion Rate (OCF/Net Income) of Co-Diagnostics changed from 77.46 % to 62.13 %, representing a -19.79% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Cash Conversion Rate (OCF/Net Income) Co-Diagnostics since 2006 – with annual values, charts, and detailed analysis.

Cash conversion measures how effectively net income converts to operating cash flow. Ratios above 100% indicate high-quality, cash-backed earnings.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Cash Conversion Rate (OCF/Net Income)'s Co-Diagnostics with sector peers and the industry average to assess whether it is attractive.

To evaluate Cash Conversion Rate (OCF/Net Income)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Cash Conversion Rate (OCF/Net Income).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Co-Diagnostics

All Key Metrics — Co-Diagnostics